viewCircassia Group PLC

Circassia Pharma Plc - Result of General Meeting

RNS Number : 4839L
Circassia Pharmaceuticals Plc
30 April 2020

Result of General Meeting and Change of Name

Oxford, UK - 30 April 2020: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders. The Company will formally change its name to Circassia Group plc in the coming days, a further announcement will be made ahead of the name change being formally implemented. Upon the change of name the Company's TIDM will remain CIR and the Company's website address will continue to be www.circassia.com.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 15 April 2020 which is available on the Company's website www.circassia.com.

The transfer to AstraZeneca of the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia remains subject to competition law clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The Company filed for Hart-Scott-Rodino clearance on 23 April 2020.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.





Ian Johnson, Executive Chairman

Michael Roller, Chief Financial Officer


c/o Peel Hunt


Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Oliver Jackson


Tel: +44 (0) 20 7418 8900


finnCap (Joint Broker)

Geoff Nash / Alice Lane

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Duncan Monteith

Tel: +44 (0) 20 7260 1000



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Circassia Group PLC

Price: 25.55

Market: LSE
Market Cap: £96.3 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19